(“Ananda” or the “Company”)
Investee company iCAN signs MOU with Yom Chai for Crohn’s Disease and Autism
The Directors of
Yom Chai has deep experience in the international medical cannabis market opening and running dispensaries and production facilities as well as providing consulting services to a wide range of cannabis businesses.
Yom Chai, in collaboration with leading American and Israeli scientists and medical professionals is initially developing a formulated suppository targeting people suffering from Crohn's Disease and will develop various targeted cannabis formulations including treatment for children and adults with Autism.
iCAN will be supporting Yom Chai by combining its unique access to innovation and technology with unmatched industry insights and international connections. The signing of this MOU provides iCAN with a combination of revenue, equity and future royalties.
The directors of the Company accept responsibility for the contents of this announcement.
Ananda Developments plc+44 (0)739 269 6517 Executive Director Melissa SturgessInvestor Relations email@example.com Jeremy Sturgess-Smith Peterhouse Capital Limited+44 (0)20 7469 0930 Corporate Finance Fungai Ndoro Mark AnwylCorporate Broker Lucy Williams Duncan Vasey Celicourt Communications+44 (0)20 7520 9261 Mark Atelme Joanna Boon
Notes to editors
Ananda Developments has been established as a company to invest in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the
Ananda’s investment strategy is to invest in companies, projects or products that are either progressing medical or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.